321 related articles for article (PubMed ID: 27322586)
1. A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer.
Wei Y; Zhao W; Huang Y; Yu Q; Zhu S; Wang S; Zhao S; Hu X; Yu J; Yuan S
PLoS One; 2016; 11(6):e0157606. PubMed ID: 27322586
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.
Li L; Hu M; Zhu H; Zhao W; Yang G; Yu J
Clin Lung Cancer; 2010 Sep; 11(5):335-40. PubMed ID: 20837459
[TBL] [Abstract][Full Text] [Related]
3. Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study.
Yue J; Yang Y; Cabrera AR; Sun X; Zhao S; Xie P; Zheng J; Ma L; Fu Z; Yu J
Dis Esophagus; 2012 Jan; 25(1):54-61. PubMed ID: 21595781
[TBL] [Abstract][Full Text] [Related]
4. ¹⁸F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with ¹⁸F-FMISO.
Chen L; Zhang Z; Kolb HC; Walsh JC; Zhang J; Guan Y
Nucl Med Commun; 2012 Oct; 33(10):1096-102. PubMed ID: 22836736
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Hypermetabolic and Hypoxic Volumes Delineated on [
Thureau S; Modzelewski R; Bohn P; Hapdey S; Gouel P; Dubray B; Vera P
Mol Imaging Biol; 2020 Jun; 22(3):764-771. PubMed ID: 31432388
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma.
Grönroos T; Bentzen L; Marjamäki P; Murata R; Horsman MR; Keiding S; Eskola O; Haaparanta M; Minn H; Solin O
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):513-20. PubMed ID: 14722675
[TBL] [Abstract][Full Text] [Related]
7. [Value of 18F-FETNIM PET-CT for detection of tumor hypoxia in non-small-cell lung cancer].
Hu M; Kong L; Zhao SQ; Yang GR; Yang WF; Han AQ; Fu Z; Ma L; Zheng JS; Yu JM
Zhonghua Zhong Liu Za Zhi; 2010 Jun; 32(6):463-6. PubMed ID: 20819492
[TBL] [Abstract][Full Text] [Related]
8. To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [
Li L; Wei Y; Huang Y; Yu Q; Liu W; Zhao S; Zheng J; Lu H; Yu J; Yuan S
Mol Imaging Biol; 2018 Dec; 20(6):1061-1067. PubMed ID: 29623510
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy.
Eschmann SM; Paulsen F; Reimold M; Dittmann H; Welz S; Reischl G; Machulla HJ; Bares R
J Nucl Med; 2005 Feb; 46(2):253-60. PubMed ID: 15695784
[TBL] [Abstract][Full Text] [Related]
10. Tumor Hypoxia Response After Targeted Therapy in EGFR-Mutant Non-Small Cell Lung Cancer: Proof of Concept for FMISO-PET.
Arvold ND; Heidari P; Kunawudhi A; Sequist LV; Mahmood U
Technol Cancer Res Treat; 2016 Apr; 15(2):234-42. PubMed ID: 25759424
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia imaging with 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer.
Hu M; Xing L; Mu D; Yang W; Yang G; Kong L; Yu J
Clin Nucl Med; 2013 Aug; 38(8):591-6. PubMed ID: 23797219
[TBL] [Abstract][Full Text] [Related]
12. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
13. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
[TBL] [Abstract][Full Text] [Related]
14. Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia.
Piert M; Machulla H; Becker G; Stahlschmidt A; Patt M; Aldinger P; Dissmann PD; Fischer H; Bares R; Becker HD; Lauchart W
Eur J Nucl Med; 1999 Feb; 26(2):95-109. PubMed ID: 9933343
[TBL] [Abstract][Full Text] [Related]
15. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET.
Lehtiö K; Oikonen V; Grönroos T; Eskola O; Kalliokoski K; Bergman J; Solin O; Grénman R; Nuutila P; Minn H
J Nucl Med; 2001 Nov; 42(11):1643-52. PubMed ID: 11696633
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic Analysis of Dynamic
Schwartz J; Grkovski M; Rimner A; Schöder H; Zanzonico PB; Carlin SD; Staton KD; Humm JL; Nehmeh SA
J Nucl Med; 2017 Jun; 58(6):911-919. PubMed ID: 28232611
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitizing effect of irisquinone on glioma through the downregulation of HIF-1α evaluated by 18F-FDG and 18F-FMISO PET/CT.
Wang H; Zhang Y; Yu W; Zhao X; Xue Y; Xu H
Nucl Med Commun; 2016 Jul; 37(7):705-14. PubMed ID: 26963468
[TBL] [Abstract][Full Text] [Related]
18. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model.
Dubois L; Landuyt W; Cloetens L; Bol A; Bormans G; Haustermans K; Labar D; Nuyts J; Grégoire V; Mortelmans L
Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):209-18. PubMed ID: 18690432
[TBL] [Abstract][Full Text] [Related]
19.
Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
[TBL] [Abstract][Full Text] [Related]
20. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.
Yang DJ; Wallace S; Cherif A; Li C; Gretzer MB; Kim EE; Podoloff DA
Radiology; 1995 Mar; 194(3):795-800. PubMed ID: 7862981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
